- Home
- TENX vs ANL Comparison
TENX vs ANL Comparison
Compare TENX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TENX | ANL |
|---|---|---|
| Founded | 1967 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | TENX | ANL |
|---|---|---|
| Price | $12.17 | $1.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | 211.3K | ★ 1.2M |
| Earning Date | 11-12-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $0.88 |
| 52 Week High | $14.22 | $2.99 |
Technical Indicators
Market Signals| Indicator | TENX | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | 46.01 |
| Support Level | $11.70 | $1.17 |
| Resistance Level | $13.00 | $2.01 |
| Average True Range (ATR) | 0.98 | 0.22 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 55.63 | 22.62 |
Price Performance
Historical ComparisonAbout TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.